Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Tóm tắt
Từ khóa
Tài liệu tham khảo
Davis, 2010, Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Nature, 463, 88, 10.1038/nature08638
Kenkre, 2012, The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways, Curr Hematol Malig Rep, 7, 216, 10.1007/s11899-012-0127-0
Wiestner, 2013, Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies, J Clin Oncol, 31, 128, 10.1200/JCO.2012.44.4281
Gururajan, 2006, Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma, J Immunol, 176, 5715, 10.4049/jimmunol.176.10.5715
Rushworth, 2013, BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB, Cell Signal, 25, 106, 10.1016/j.cellsig.2012.09.008
Honigberg, 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci USA, 107, 13075, 10.1073/pnas.1004594107
de Rooij, 2012, The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia, Blood, 119, 2590, 10.1182/blood-2011-11-390989
Ponader, 2012, The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo, Blood, 119, 1182, 10.1182/blood-2011-10-386417
Herman, 2011, Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765, Blood, 117, 6287, 10.1182/blood-2011-01-328484
Advani, 2013, Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies, J Clin Oncol, 31, 88, 10.1200/JCO.2012.42.7906
Byrd, 2013, Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, N Engl J Med, 369, 32, 10.1056/NEJMoa1215637
Gribben, 2011, Update on therapy of chronic lymphocytic leukemia, J Clin Oncol, 29, 544, 10.1200/JCO.2010.32.3865
Byrd, 2005, Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011, Blood, 105, 49, 10.1182/blood-2004-03-0796
Tam, 2008, Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia, Blood, 112, 975, 10.1182/blood-2008-02-140582
Byrd, 2006, Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy, J Clin Oncol, 24, 437, 10.1200/JCO.2005.03.1021
Hallek, 2010, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, Lancet, 376, 1164, 10.1016/S0140-6736(10)61381-5
Catovsky, 2007, Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial, Lancet, 370, 230, 10.1016/S0140-6736(07)61125-8
Eichhorst, 2009, First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia, Blood, 114, 3382, 10.1182/blood-2009-02-206185
Woyach, 2013, Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies, J Clin Oncol, 31, 440, 10.1200/JCO.2011.41.5646
Goede, 2013, Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in, Leukemia, 27, 1172, 10.1038/leu.2012.252
Hallek, 2008, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, 111, 5446, 10.1182/blood-2007-06-093906
Jaffe, 2008, Classification of lymphoid neoplasms: the microscope as a tool for disease discovery, Blood, 112, 4384, 10.1182/blood-2008-07-077982
Hallek, 2012, Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes, Blood
Cheson, 2012, Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia, J Clin Oncol, 30, 2820, 10.1200/JCO.2012.43.3748
Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol, 25, 579, 10.1200/JCO.2006.09.2403
Claus, 2012, Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia, J Clin Oncol, 30, 2483, 10.1200/JCO.2011.39.3090
Knauf, 2009, Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia, J Clin Oncol, 27, 4378, 10.1200/JCO.2008.20.8389
Hillmen, 2007, Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia, J Clin Oncol, 25, 5616, 10.1200/JCO.2007.12.9098
Goede, 2013, Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab versus Clb alone in patients with chronic lymphocytic leukemia and preexisting medical conditions (comorbidities): final stage 1 results of the CLL11 (BO21004) phase III trial, Proc Am Soc Clin Oncol, 31
Goede V, Fischer K, Kreuzer K-A, et al. Kinetics of blood cell subpopulations during treatment with obinutuzumab (GA101) + chlorambucil (GClb), rituximab +Clb (RClb) versus Clb alone in patients with chronic lymphocytic leukemia and coexisting medical conditions: stage I results of the CLL11 (BO21004) trial. Biennial International Workshop on CLL (iwCLL) 2013; Sept 9–11, 2013; Cologne, Germany: abstr 4.14.
Badoux, 2011, Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia, Blood, 118, 3489, 10.1182/blood-2011-03-339077
Burger, 2012, The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients, Blood, 120, 187, 10.1182/blood.V120.21.187.187
Ferrajoli, 2005, Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients, Leuk Lymphoma, 46, S87
Keating, 2005, Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia, J Clin Oncol, 23, 4079, 10.1200/JCO.2005.12.051